Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

Engvall, 1971, Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G, Immunochemistry, 8, 871, 10.1016/0019-2791(71)90454-X

Van Weemen, 1971, Immunoassay using antigen–enzyme conjugates, FEBS Lett, 15, 232, 10.1016/0014-5793(71)80319-8

Gheesling, 1994, Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay, J Clin Microbiol, 32, 1475, 10.1128/JCM.32.6.1475-1482.1994

Player, 1993, Comparison of an ELISA system for the quantification of hepatitis B antibody with an automated and a semi-automated system, J Virol Methods, 45, 67, 10.1016/0166-0934(93)90140-M

Voller, 1978, Enzyme immunoassays with special reference to ELISA techniques, J Clin Pathol, 31, 507, 10.1136/jcp.31.6.507

Macy, 1988, Enhanced ELISA: how to measure less than 10picograms of a specific protein (immunoglobulin) in less than 8hours, Faseb J, 2, 3003, 10.1096/fasebj.2.14.3263291

Jitsukawa, 1989, Increased coating efficiency of antigens and preservation of original antigenic structure after coating in ELISA, J Immunol Methods, 116, 251, 10.1016/0022-1759(89)90211-1

McLaren, 1981, Indirect enzyme linked immunosorbent assay (ELISA): practical aspects of standardization and quality control, Med Lab Sci, 38, 245

Ravindranath, 1994, Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA, J Immunol Methods, 169, 257, 10.1016/0022-1759(94)90270-4

Engvall, 1972, Enzyme-linked immunosorbent assay. ELISA. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes, J Immunol, 109, 129, 10.4049/jimmunol.109.1.129

Plested, 2003, ELISA, Methods Mol Med, 71, 243

Engvall, 1977, Quantitative enzyme immunoassay (ELISA) in microbiology, Med Biol, 55, 193

Miles, 2002, Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials, Protein Expr Purif, 25, 87, 10.1006/prep.2001.1613

Zou, 2003, Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials, Vaccine, 21, 1650, 10.1016/S0264-410X(02)00701-6

Kennedy, 2002, In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response, Infect Immun, 70, 6948, 10.1128/IAI.70.12.6948-6960.2002

Malkin, 2005, Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria, Vaccine, 23, 3131, 10.1016/j.vaccine.2004.12.019

Malkin, 2005, Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria, Infect Immun, 73, 3677, 10.1128/IAI.73.6.3677-3685.2005

Malkin, 2007, Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria, PLoS Clin Trials, 2, e12, 10.1371/journal.pctr.0020012